CareDx's AlloHeme AI Test Poised to Reshape Post-Transplant Cancer Care

BRISBANE, CA – February 03, 2026 – The landscape of post-transplant cancer surveillance may be on the verge of a significant transformation. This week, the transplant and cellular therapy community is turning its attention to Salt Lake City, where precision medicine company CareDx is set to unveil pivotal data on its groundbreaking AlloHeme™ test. The complete 24-month results from a major clinical trial will be presented at the 2026 Tandem Meetings, and they could validate a new, AI-powered method for detecting cancer relapse far earlier than current standards allow.

For patients with aggressive blood cancers like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), an allogeneic hematopoietic cell transplant (HCT) can be a life-saving procedure. Yet, the shadow of relapse looms large, remaining the primary cause of death for many. The upcoming presentation by Dr. Ran Reshef of Columbia University could signal a new era of proactive monitoring, offering clinicians and patients a critical advantage in the race against time.

A New Paradigm in Surveillance

The core challenge in post-HCT care is identifying the resurgence of cancer cells before they cause a full-blown clinical relapse. Traditional surveillance methods, such as Short Tandem Repeat (STR) testing, monitor for "chimerism"—the mixture of donor and recipient cells in the patient's blood. While useful, these methods often lack the sensitivity to detect the earliest signs of trouble, leaving a dangerously narrow window for intervention.

This is the problem AlloHeme was designed to solve. CareDx's test leverages the power of next-generation sequencing (NGS) to analyze a patient's blood with unprecedented depth. By applying a sophisticated AI algorithm to the NGS data, AlloHeme can identify minute changes in chimerism that signal the re-emergence of malignant cells. This "ultra-sensitive" approach promises to find the needle in the haystack much sooner than was previously possible.

The integration of AI is a key differentiator. CareDx has been building its expertise in using predictive analytics to turn complex molecular data into actionable clinical insights. With AlloHeme, this strategy is being applied to one of oncology's most difficult challenges, moving beyond simple detection to predictive risk assessment.

The ACROBAT Study: Validating the Promise

The data fueling this optimism comes from the ACROBAT study (NCT04635384), a prospective, multi-center, blinded clinical trial conducted at 11 top transplant centers across the United States. The study was specifically designed to rigorously evaluate AlloHeme's ability to monitor for relapse in AML and MDS patients following a transplant. The presentation at the Tandem Meetings on Friday will reveal the complete 24-month follow-up data, a key milestone for clinical validation.

While the full dataset remains under wraps until the presentation, a look at the 12-month interim results, presented at the 2025 Tandem Meetings, provides a compelling preview of AlloHeme's potential. That earlier analysis, which included 229 patients, demonstrated remarkable performance:

• High Accuracy: The test achieved a sensitivity of 93% and a specificity of 88%, indicating it is highly effective at both correctly identifying patients who will relapse and those who will not.
• Significant Lead Time: Most critically, AlloHeme detected impending relapse a median of 36 days before it was identifiable by traditional methods or clinical symptoms.
• Superior Performance: In a head-to-head statistical comparison, AlloHeme's diagnostic accuracy, measured as Area Under the Curve (AUC), was 0.90. This significantly outperformed conventional STR testing, which scored much lower at 0.74 and 0.61 depending on the threshold used.

Following the interim data release, Dr. Monzr M. Al Malki of City of Hope National Medical Center, who presented the findings, remarked, "This study gets us one step closer to having a highly reliable molecular biomarker that enables us to assess the status of the stem cell engraftment and predict risk of relapse."

The Human Impact: A 36-Day Window of Hope

For a patient recovering from a hematopoietic cell transplant, a month can feel like a lifetime. The 36-day median lead time demonstrated in the ACROBAT interim analysis is not just a statistic; it represents a crucial window of opportunity. This period allows oncologists to move from a reactive to a proactive stance.

Relapse rates after HCT for AML can be as high as 25-55%, and the prognosis after a relapse occurs is grim, with two-year survival rates often below 25%. Early detection of measurable residual disease (MRD) is widely seen by experts as the key to changing this narrative. With weeks of advance warning, clinicians could initiate preemptive therapies, such as adjusting immunosuppression, administering donor lymphocyte infusions, or starting targeted drug therapies, to intercept the cancer's return before it gains a foothold.

This shift could dramatically improve patient outcomes, potentially increasing survival rates, reducing the need for more intensive and toxic salvage therapies, and alleviating the profound anxiety that comes with the uncertainty of post-transplant life. By providing a clearer, earlier view of what's happening at the molecular level, AlloHeme aims to give patients a better chance at a durable cure.

Market Dynamics and CareDx's Strategic Play

The launch of AlloHeme would also mark a significant strategic move for CareDx. While the company is a dominant player in diagnostics for solid organ transplants (heart, kidney, lung), AlloHeme represents a major expansion into the large and rapidly growing field of hematology-oncology.

The global market for hematologic malignancy testing was valued at over $3.5 billion in 2023 and is projected to surge to $13.5 billion by 2033. This growth is fueled by an increasing incidence of blood cancers and rapid advancements in diagnostic technologies like NGS. The market is competitive, with major players like Illumina, Thermo Fisher, and Quest Diagnostics, but the demand for more sensitive and predictive tools for MRD monitoring creates a substantial opportunity.

Marica Grskovic, CareDx's Chief Strategy Officer, noted after the interim data release that the results "build upon our growth strategy to expand into hematology oncology." She emphasized that giving clinicians "significant lead time they need to intervene sooner" is the test's core value proposition.

All eyes are now on the full 24-month data to be presented by Dr. Reshef. Confirmation of the strong interim results would provide powerful momentum for CareDx as it prepares for commercialization. The company has already scheduled an investor webcast for February 12, 2026, to discuss the study findings in detail and, crucially, to outline its commercial launch timeline. This indicates a high degree of confidence and a clear intent to bring AlloHeme to clinicians and patients in the near future, pending any regulatory steps. The presentation this week could be the starting gun for a new standard in cancer care.